Idiopathic pulmonary fibrosis (IPF) is one of interstitial lung diseases that are characterized by excessive matrix deposition and destruction of the normal lung architecture. There has been a shift in the paradigm of IPF with the progression of IPF study, in recent years. From being considered as a predominantly inflammatory lung disease, now it has shifted to a disease characterized by epithelial injury, abnormal epithelial healing and subsequent fibroproliferative response. Correspondingly, the view on the therapy of IPF has also changed a lot. We make an outline to current treatment progress of IPF in this review.